AstraZeneca’s quick Covid-19 vaccine trial restart splits experts

There should be scrutiny over whether the process has had enough time to properly evaluate if more such events could occur later in the trial or in the general population, especially given the Covid-19 vaccine race. Credit: Shutterstock.



  • AZD1222